Developing H2 relaxin analog – B7-33 – as antifibrotic therapy
Fibrosis (tissue scarring) results from an aberrant wound-healing response to organ injury and contributes to organ dysfunction and failure through excessive extracellular matrix (primarily collagen) build-up in fibrosis and fibrosis-related diseases (e.g. heart, kidney failure). These medical problems contribute to more than 45% of deaths globally.
Currently, available therapies (e.g., ACE inhibitors, ARBs) only delay disease progression by months and can induce severe side effects after chronic administration. Novel anti-fibrotic therapies that are safe and can renormalise organ function are needed.
Aims
- Produce relaxin hormone-based peptides analogues.
- Develop drug candidates for novel anti-fibrotic therapies.
We’ll produce relaxin hormone-based peptides analogues that are shown to have strong anti-fibrotic effects. Using modern solid-phase peptide synthesis (SPPS), rational and structure-based design, we’ll develop drug candidates. The preclinical analogues will be tested in cell-based assays (RXFP1 cells, binding, and cAMP potency) and in animal models of fibrosis.
Research team
Research group
Take part in this project
Student applications
Students who are applying to study at The Florey can register their interest in this project. Refer to our step-by-step guide to help you with your application.
Contact us
If you’re interested in learning more about this project please contact our team.
